TLR8 and neoplasm: As an agonist of TLR7 and TLR8, resiquimod (R848)-loaded β-cyclodextrin nanoparticles (CDNP-R848) induced a repolarization of M2-like TAMs shifted toward a M1-like TAM phenotype, leading to the reduction of tumor growth in multiple murine tumor models [203].